Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc (ENTA) Historical Volatility
ENTA's 30 day historical volatility is 56.65%, in the 90th percentile of readings over the past year. This is a high percentile, meaning Enanta Pharmaceuticals Inc shares have swung far more than usual. ENTA's 30 day implied volatility sits at 100.13%, with an IV Rank of 62.30%, leaving IV 43.48 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking ENTA historical volatility helps you see how much Enanta Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ENTA's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ENTA 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ENTA's 30 day historical volatility, or ENTA HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ENTA's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →